Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico
Gastric atrophy increases the risk of gastric cancer due to changes in gastric glands and secretory function. Gastric cancer is a global concern, especially in regions such as South America and East Asia. In Ecuador, it is the leading cause of death, which makes it a major public health problem. The...
Saved in:
| Main Author: | |
|---|---|
| Format: | bachelorThesis |
| Language: | spa |
| Published: |
2024
|
| Subjects: | |
| Online Access: | https://dspace.unl.edu.ec/jspui/handle/123456789/30468 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Add Tag | _version_ | 1857833031900856320 |
|---|---|
| author | García Vélez, Paola Lissette |
| author_facet | García Vélez, Paola Lissette |
| author_role | author |
| collection | Repositorio Universidad Nacional de Loja |
| dc.contributor.none.fl_str_mv | Delgado, Iliana Alicia |
| dc.creator.none.fl_str_mv | García Vélez, Paola Lissette |
| dc.date.none.fl_str_mv | 2024-08-15T15:07:14Z 2024-08-15T15:07:14Z 2024-08-15 |
| dc.format.none.fl_str_mv | 54 páginas application/pdf |
| dc.identifier.none.fl_str_mv | https://dspace.unl.edu.ec/jspui/handle/123456789/30468 |
| dc.language.none.fl_str_mv | spa |
| dc.publisher.none.fl_str_mv | Loja |
| dc.rights.none.fl_str_mv | http://creativecommons.org/licenses/by-nc-sa/3.0/ec/ info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:Repositorio Universidad Nacional de Loja instname:Universidad Nacional de Loja instacron:UNL |
| dc.subject.none.fl_str_mv | LABORATORIO CLÍNICO PEPSINÓGENO GASTRITIS ATRÓFICA BIOMARCADOR |
| dc.title.none.fl_str_mv | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/bachelorThesis |
| description | Gastric atrophy increases the risk of gastric cancer due to changes in gastric glands and secretory function. Gastric cancer is a global concern, especially in regions such as South America and East Asia. In Ecuador, it is the leading cause of death, which makes it a major public health problem. The aim of this study is to evaluate the clinical utility of the pepsinogen I/II ratio as a noninvasive biomarker to detect both gastric atrophy and stomach cancer, analyzing its sensitivity, specificity and supportive diagnostic value. For this purpose, a systematic review of the Pubmed, Scielo, Lilacs and Cochrane Library databases was carried out, using the PRISMA method for the selection of publications between 2012 and 2022, excluding gray literature. Thirteen studies were included in this systematic review, evaluated with the JBI tool, which showed moderate to low bias. These studies indicated that the pepsinogen I/II ratio has a sensitivity of 71% and specificity of 83% for detecting gastric atrophy, and a sensitivity of 80% and specificity of 77% for gastric cancer. In addition, twelve studies demonstrated its efficacy as a diagnostic test using the AUC measure, with values of 0.71 for gastric atrophy and 0.80 for cancer. Thus, the pepsinogen I/II ratio shows fair sensitivity and good specificity in the detection of gastric atrophy, and good sensitivity and fair specificity in the case of gastric cancer. The pepsinogen I/II ratio has a regular efficacy for diagnosing gastric atrophy and good for gastric cancer, but its efficiency may be affected by several factors related to diversity and differences between populations and studies performed |
| eu_rights_str_mv | openAccess |
| format | bachelorThesis |
| id | UNL_20dfdcfbfcda2e2d66ed5f7de481ebd8 |
| instacron_str | UNL |
| institution | UNL |
| instname_str | Universidad Nacional de Loja |
| language | spa |
| network_acronym_str | UNL |
| network_name_str | Repositorio Universidad Nacional de Loja |
| oai_identifier_str | oai:dspace.unl.edu.ec:123456789/30468 |
| publishDate | 2024 |
| publisher.none.fl_str_mv | Loja |
| reponame_str | Repositorio Universidad Nacional de Loja |
| repository.mail.fl_str_mv | * |
| repository.name.fl_str_mv | Repositorio Universidad Nacional de Loja - Universidad Nacional de Loja |
| repository_id_str | 0 |
| rights_invalid_str_mv | http://creativecommons.org/licenses/by-nc-sa/3.0/ec/ |
| spelling | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástricoGarcía Vélez, Paola LissetteLABORATORIO CLÍNICOPEPSINÓGENOGASTRITIS ATRÓFICABIOMARCADORGastric atrophy increases the risk of gastric cancer due to changes in gastric glands and secretory function. Gastric cancer is a global concern, especially in regions such as South America and East Asia. In Ecuador, it is the leading cause of death, which makes it a major public health problem. The aim of this study is to evaluate the clinical utility of the pepsinogen I/II ratio as a noninvasive biomarker to detect both gastric atrophy and stomach cancer, analyzing its sensitivity, specificity and supportive diagnostic value. For this purpose, a systematic review of the Pubmed, Scielo, Lilacs and Cochrane Library databases was carried out, using the PRISMA method for the selection of publications between 2012 and 2022, excluding gray literature. Thirteen studies were included in this systematic review, evaluated with the JBI tool, which showed moderate to low bias. These studies indicated that the pepsinogen I/II ratio has a sensitivity of 71% and specificity of 83% for detecting gastric atrophy, and a sensitivity of 80% and specificity of 77% for gastric cancer. In addition, twelve studies demonstrated its efficacy as a diagnostic test using the AUC measure, with values of 0.71 for gastric atrophy and 0.80 for cancer. Thus, the pepsinogen I/II ratio shows fair sensitivity and good specificity in the detection of gastric atrophy, and good sensitivity and fair specificity in the case of gastric cancer. The pepsinogen I/II ratio has a regular efficacy for diagnosing gastric atrophy and good for gastric cancer, but its efficiency may be affected by several factors related to diversity and differences between populations and studies performedLa atrofia gástrica aumenta el riesgo de cáncer gástrico debido a cambios en las glándulas gástricas y la función secretora. El cáncer gástrico es una preocupación global, especialmente en regiones como América del Sur y Asia oriental. En Ecuador, es la principal causa de muerte, lo que lo convierte en un problema de salud pública importante. El objetivo de este estudio es evaluar la utilidad clínica del cociente pepsinógeno I/II como biomarcador no invasivo para detectar tanto la atrofia gástrica como el cáncer estomacal, analizando su sensibilidad, especificidad y valor diagnóstico de apoyo. Para ello, se llevó a cabo una revisión sistemática de las bases de datos Pubmed, Scielo, Lilacs y la Biblioteca Cochrane, utilizando el método PRISMA para la selección de publicaciones entre 2012 y 2022, excluyendo la literatura gris. Se incluyeron trece estudios en esta revisión sistemática, evaluados con la herramienta JBI, que mostraron un sesgo moderado a bajo. Estos estudios indicaron que el cociente pepsinógeno I/II tiene una sensibilidad del 71% y una especificidad del 83% para detectar la atrofia gástrica, y una sensibilidad 80% y especificidad del 77% para el cáncer gástrico. Además, doce estudios demostraron su eficacia como prueba diagnóstica mediante la medida AUC, con valores de 0,71 para la atrofia gástrica y 0,80 para el cáncer. Por tanto, el cociente pepsinógeno I/II muestra una sensibilidad regular y una buena especificidad en la detección de la atrofia gástrica, y una sensibilidad buena y especificidad regular en el caso del cáncer gástrico. El cociente pepsinógeno I/II tiene una eficacia regular para diagnosticar la atrofia gástrica y buena para el cáncer gástrico, pero su eficiencia puede verse afectada por varios factores relacionados con la diversidad y las diferencias entre las poblaciones y los estudios realizadosLojaDelgado, Iliana Alicia2024-08-15T15:07:14Z2024-08-15T15:07:14Z2024-08-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesis54 páginasapplication/pdfhttps://dspace.unl.edu.ec/jspui/handle/123456789/30468spahttp://creativecommons.org/licenses/by-nc-sa/3.0/ec/info:eu-repo/semantics/openAccessreponame:Repositorio Universidad Nacional de Lojainstname:Universidad Nacional de Lojainstacron:UNL2025-05-02T15:12:14Zoai:dspace.unl.edu.ec:123456789/30468Institucionalhttps://dspace.unl.edu.ec/Universidad públicahttps://unl.edu.ec/https://dspace.unl.edu.ec/oaiEcuador***opendoar:02025-05-02T15:12:14falseInstitucionalhttps://dspace.unl.edu.ec/Universidad públicahttps://unl.edu.ec/https://dspace.unl.edu.ec/oai*Ecuador***opendoar:02025-05-02T15:12:14Repositorio Universidad Nacional de Loja - Universidad Nacional de Lojafalse |
| spellingShingle | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico García Vélez, Paola Lissette LABORATORIO CLÍNICO PEPSINÓGENO GASTRITIS ATRÓFICA BIOMARCADOR |
| status_str | publishedVersion |
| title | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| title_full | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| title_fullStr | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| title_full_unstemmed | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| title_short | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| title_sort | Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico |
| topic | LABORATORIO CLÍNICO PEPSINÓGENO GASTRITIS ATRÓFICA BIOMARCADOR |
| url | https://dspace.unl.edu.ec/jspui/handle/123456789/30468 |